10yr ffup data on 49pts from the OG CRESPA study (GOL vs PBO in very early pSpA): 81.6% (40/49) were in clinical remission 15 pts on drug-free remission 21 pts w/remission on meds still on GOL, no unSSAEs Early aggressive tx is key! AbsPOS0931 @RheumNow #EULAR2026 https://t.co/HrTF5XtAZt

• https://x.com/RHEUMarampa/status/2062797311827210457/photo/1
• https://x.com/RHEUMarampa/status/2062797311827210457/photo/1

This study describes the SIJ differences in axSpA vs. non-axSpA pts with CBP axSpA: BME w/ widespread distribution & inflamm⬇️ over time non-axSpA: BME rare or limited only to ventral & middle superior sacrum Findings may improve MRI ID of axSpa AbsPOS0193 @RheumNow #EULAR2026 https://t.co/7eiHQOOIWs

• https://x.com/RHEUMarampa/status/2062657491662471252/photo/1

Gecacitinib 100mg BiD vs PBO in active r-axSpA: Met primary endpt ASAS40 at wk 16 showing efficacy of gecacitinib vs. PBO (51.9%vs12.9%,p<0.0001) Gecacitinib showed ⬆️ improvements in ASDAS-CRP, physical fnxn, spinal mobility & QOL Promising tx. AbsOP0240 @RheumNow #EULAR2026 https://t.co/FytoRgxvnG

• https://x.com/RHEUMarampa/status/2062650609497481580/photo/1
• https://x.com/RHEUMarampa/status/2062650609497481580/photo/1

One of the main changes in the 2025 update on the EULAR guidelines for imaging in SpA is that of MRI replacing CR as the initial imaging modality while CR & low dose CT of SIJs became alternative modalities in the absence of or if with CIs to MRI AbsPOS0682 @RheumNow #EULAR2026 https://t.co/bj2NWKnIGf

• https://x.com/RHEUMarampa/status/2062647198328701331/photo/1

Treat-to-target in inflammatory arthritis recommended by every guideline. Followed in only 40% of SpA visits. The main reason was activity simply wasn’t documented using a validated index. You can’t target what you don’t measure. Abstr 0351 @ RheumNow #EULAR2026 #axSpA #PsA https://t.co/VAcoZfCXsR

• https://x.com/synovialjoints/status/2062797701712859211/photo/1

💉Do GLP-1 agonists improve DMARD persistence in PsA/axSpA? TriNetX real-world study (n=3,068): YES! Better b/tsDMARD persistence and lower stroke & mortality risk #POS0194 #EULAR2026 @rheumnow

⏰ The question rheumatologists keep asking: Does early axSpA diagnosis reduce long-term spinal damage? Answer from the SCQM registry (n=376): Early diagnosis linked to 3.85 fewer mSASSS points long-term, esp. in HLA-B27+ males #POS0191 #EULAR2026 @RheumNow https://t.co/HM5kvqXMEh

• https://x.com/Nellziade/status/2062595567683793172/photo/1

📋 Do 2025 ASAS-SPARTAN criteria classify fewer real-world axSpA patients? Data from the RABBIT-SpA registry (n=2,236) confirms: 67% vs 73% with 2009 criteria Clinical arm rarely fulfilled #POS0190 #EULAR2026 @RheumNow https://t.co/HYie4w8c6r

• https://x.com/Nellziade/status/2062594803481678047/photo/1

🔍 Do posterior element lesions progress over 10 years in axSpA? Data from the DESIR inception cohort (n=320) says RARELY! But baseline PE inflammation raises facet ankylosis risk ~70-fold #POS0189 #EULAR2026 @RheumNow https://t.co/PdwlPGjKqK

• https://x.com/Nellziade/status/2062594452556837170/photo/1

CyTOF reveals significant sexual dimorphism in monocyte populations in active #axSpA Women show reduced classical and non-classical monocytes vs healthy controls. Men do not show the same pattern. Sex is not just a demographic variable in AxSpA it is also an immunological one.

Ivarmacitinib (selective JAK1 inhibitor) significantly improved ASAS40 vs placebo in nr-#axSpA(39.7% vs 24.8%; p=0.006) at 12 weeks, sustained to 24 weeks. Another oral option for non-radiographic disease. Abstr OP0237 @RheumNow #EULAR2026